Jazz Pharma Becomes 25th Drugmaker to Restrict Participation in 340B Program
Jazz Pharmaceuticals has become the 25th drugmaker to reduce its participation in the controversial 340B Discount Drug Program.
Source: Drug Industry Daily
Jazz Pharmaceuticals has become the 25th drugmaker to reduce its participation in the controversial 340B Discount Drug Program.
Source: Drug Industry Daily